Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:02:17 2024-05-28 pm EDT			5-day change	1st Jan Change
3.125 ^USD	-9.16%		-11.58%	+111.49%

May. 02	Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02	Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024 at 04:06 pm EDT

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.

Details of the presentations can be found below.

H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Location: The Nasdaq Headquarters, New York City
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 05/20/2024
Time: 2:30 PM ET

Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Location: Virtual
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 05/29/2024
Time: 1:30 PM ET

Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Grace Spencer
Taft Communications
609-583-1151
grace@taftcommunications.com

Source: Cardiff Oncology, Inc.

2024 GlobeNewswire, Inc., source Press Releases

Latest news about Cardiff Oncology, Inc.

Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	Apr. 08	CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	Mar. 06	MT
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care	Mar. 01	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	Mar. 01	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	Mar. 01	MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	Feb. 29	CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	Feb. 29	CI
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Top Premarket Gainers	23-09-27	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Cardiff Oncology Reports 'Positive' Results From Onvansertib Monotherapy Trial for Pancreatic, Small Cell Lung Cancers	23-09-26	MT
Transcript : Cardiff Oncology, Inc. - Special Call	23-09-26
Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy	23-09-26	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating	23-08-11	MT
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Sector Update: Health Care Stocks Gaining Late Tuesday	23-08-08	MT
Sector Update: Health Care	23-08-08	MT

Chart Cardiff Oncology, Inc.

Duration

Period

More charts

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - TD Cowen Oncology Innovation Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Cardiff Oncology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.44 USD

Average target price

9.833 USD

Spread / Average Target

+185.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARDIFF ONCOLOGY, INC.	+111.49%	154M
MODERNA, INC.	+51.65%	63.85B
IQVIA HOLDINGS INC.	-2.44%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.41%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.55%	18.69B
BIO-TECHNE CORPORATION	+2.53%	12.73B
UNITED THERAPEUTICS CORPORATION	+21.57%	12.11B
MEDPACE HOLDINGS, INC.	+28.01%	12.07B

Other Biotechnology & Medical Research